RO130480A2 - Chewable tablets with anti-inflammatory and antialgic effects, to be used in pharyngitis - Google Patents
Chewable tablets with anti-inflammatory and antialgic effects, to be used in pharyngitis Download PDFInfo
- Publication number
- RO130480A2 RO130480A2 ROA201300916A RO201300916A RO130480A2 RO 130480 A2 RO130480 A2 RO 130480A2 RO A201300916 A ROA201300916 A RO A201300916A RO 201300916 A RO201300916 A RO 201300916A RO 130480 A2 RO130480 A2 RO 130480A2
- Authority
- RO
- Romania
- Prior art keywords
- inflammatory
- oil
- antialgic
- chewable tablets
- pharyngitis
- Prior art date
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Comprimate masticabile cu acțiune antiinflamatorie și antialgică folosite pentru faringiteChewable tablets with anti-inflammatory and anti-allergic action used for pharyngitis
Invenția se referă la realizarea unor comprimate cu acțiune antiinflamatorie și antialgică folosite pentru tratamentul adjuvant al proceselor inflamatorii acute și cronice faringiene.The invention relates to the manufacture of tablets with anti-inflammatory and anti-allergic action used for the adjuvant treatment of acute and chronic pharyngeal inflammatory processes.
In literatură sunt cunoscute numeroase numeroase produse cu acțiune asupra faringitelor microbiene sau virale. Dintre acestea amintim produsul Faringosept, Dermogent 50ml și Faringoplant produse de Dacia Plant, Evitus produs de firma Hofigal, Garlicops, Imunostim, loțiunea Malavit și altele. Acestea prezintă dezavantajul că nu asigură o reducere suficientă a durerilor și arsurilor din cursul proceselor inflamatorii orofaringiene.Numerous products with action on microbial or viral pharyngitis are known in the literature. Of these we mention the product Faringosept, Dermogent 50ml and Faringoplant produced by Dacia Plant, Evitus produced by Hofigal, Garlicops, Immunostim, Malavit lotion and others. These have the disadvantage that they do not ensure a sufficient reduction of the pains and burns during the inflammatory oropharyngeal processes.
Comprimatele masticabile cu acțiune antiinflamatorie și antialgică propuse conform invenției, îmbunătățește tratamentul simptomelor faringiene , prin aceea că sunt constituite din Acid ascorbic 100-400mg/cp, de preferință 230mg/cp, Extract de Echinaceea 50-100mg/cp, de preferință 50mg, Reziduu uscat de Tinctura de propolis 3-15mg/cp, de preferință 15mg, Piper negru 0,01-8mg/cp,de preferință 6mg, Ulei de busuioc 10-40mg/cp, de preferință 30mg, Ulei de eucalipt 10-40mg/cp, de preferință 15mg, Ulei de mentă 8-30md/comprimat, de preferință 20/cp, Albastru de metilen 0,l-l,9mg/cp, de preferință 0,5mg, Sorbitol 500800mg/cp, de preferință 600mg, Maltodextrină 100-200mg/cp, de preferință 165mg/cp, Lactoză 100-150mg, de preferință 120mg/cp, Celuloză microcristalină 20-60mg/cp de preferință 40mg/cp, Manitol 40-80mg/comprimat, de preferință 60mg, alcool 60-120mg/cp, de preferință llOmg, PVP 40-60mg/cp, de preferință 54mg, Stearat de magneziu20-35mg/cp, de preferință 32mg.The chewable tablets with anti-inflammatory and anti-allergic action proposed according to the invention, improve the treatment of pharyngeal symptoms, in that they consist of ascorbic acid 100-400mg / cp, preferably 230mg / cp, Echinacea extract 50-100mg / cp, preferably 50mg, Residue dry of Propolis tincture 3-15mg / cp, preferably 15mg, Black pepper 0.01-8mg / cp, preferably 6mg, basil oil 10-40mg / cp, preferably 30mg, eucalyptus oil 10-40mg / cp , preferably 15mg, Peppermint oil 8-30md / tablet, preferably 20 / cp, Methylene blue 0, ll, 9mg / cp, preferably 0.5mg, Sorbitol 500800mg / cp, preferably 600mg, Maltodextrin 100-200mg / cp, preferably 165mg / cp, Lactose 100-150mg, preferably 120mg / cp, Microcrystalline cellulose 20-60mg / cp preferably 40mg / cp, Manitol 40-80mg / tablet, preferably 60mg, alcohol 60-120mg / cp , preferably llOmg, PVP 40-60mg / cp, preferably 54mg, Magnesium stearate20-35mg / cp, preferably 32mg.
Produsul comprimate masticabile este recomandat ca adjuvant în procese inflamatorii faringiene acute sau cronice de natură bacteriană, virală sau mixtă care determină disfagii, dureri și arsuri locale. Funcția sa se exercită prin acțiunile specifice ale componentelor sale de stimulare a sistemului imunocompetent, sau acțiune antibacteriană și antivirală locală realizată de propolis, vitamina C (Acid ascorbic), Echinaceae herba, ulei de mentă (Mentae aetheroleum), ulei eucalip (Eucalypti aetheroleum), ulei de busuioc (Ocimum basilicum), piper negru (Poligoni hydropiperis herba) și albastru de metilen.The chewable tablet product is recommended as an adjunct in bacterial, viral or mixed acute or chronic pharyngeal inflammatory processes that cause local dysphagia, pain and burns. Its function is exercised by the specific actions of its components of stimulating the immunocompetent system, or local antibacterial and antiviral action made by propolis, vitamin C (Ascorbic acid), Echinaceae herba, peppermint oil (Mentae aetheroleum), eucalyptus oil (Eucalyptiether) , basil oil (Ocimum basilicum), black pepper (Polygoni hydropiperis herba) and methylene blue.
Se dă mai jos un exemplu de realizare a invenției.The following is an example of an embodiment of the invention.
Se omogenizează Acidul ascorbic, Echinaceea, Piperul negru, Sorbitolul, Manitolul, Lactoza și se obține faza A. Se dizolvă în alcool mentolul și PVP în care ιThe ascorbic acid, Echinacea, black pepper, sorbitol, mannitol, lactose are homogenized and phase A. The menthol and PVP are dissolved in alcohol where ι
(V 2 ο 1 3 u 0 9 1 6 ( -11- 2013 se dispersează uleiul de busuioc, uleiul de eucalipt și uleiul de mentă și se obține faza B. Se dizolvă albastru de metilen în tinctura de propolis și rezultă faza C. Se înglobează faza C în faza A, iar apoi se adaugă faza și faza B. In continuare produsul se trece prin moară, se granulează și se usucă în uscătorul în strat fluidizat. Granulatul obținut se omogenizează cu celuloză microcristalină, talc și stearat de magneziu, după care se introduce la mașina de comprimat.(V 2 ο 1 3 u 0 9 1 6 (-11- 2013, the basil, eucalyptus and peppermint oil are dispersed and phase B is obtained. The methylene blue is dissolved in the propolis tincture and the C phase is obtained. Include Phase C in Phase A, and then Phase and Phase B are added. The product is then passed through the mill, granulated and dried in the dryer in a fluidized layer, the granulate obtained is homogenized with microcrystalline cellulose, talc and magnesium stearate, after which is inserted into the tablet machine.
Comprimatele obținute prezintă avantajul că sunt active în procesele inflamatorii faringiene acute sau cronice, constituind un tratament adjuvant în astfel de situații.The tablets obtained have the advantage that they are active in acute or chronic pharyngeal inflammatory processes, constituting an adjuvant treatment in such situations.
Bibliografie:Popovici Iuliana, Dumitru Lupuleasa:Tehnologie Farmaceutică, pg.385, voi.III, Editura Polirom, Iași, 2009 (7V-2O13 ύ'0 9 1^-Bibliography: Popovici Iuliana, Dumitru Lupuleasa: Pharmaceutical Technology, pg. 385, vol. III, Polirom Publishing House, Iași, 2009 (7 V -2O13 ύ'0 9 1 ^ -
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ROA201300916A RO130480B1 (en) | 2013-11-28 | 2013-11-28 | Chewable tablets as adjuvants in the treatment of acute and chronic pharyngitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ROA201300916A RO130480B1 (en) | 2013-11-28 | 2013-11-28 | Chewable tablets as adjuvants in the treatment of acute and chronic pharyngitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RO130480A2 true RO130480A2 (en) | 2015-08-28 |
| RO130480B1 RO130480B1 (en) | 2019-02-28 |
Family
ID=53939503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ROA201300916A RO130480B1 (en) | 2013-11-28 | 2013-11-28 | Chewable tablets as adjuvants in the treatment of acute and chronic pharyngitis |
Country Status (1)
| Country | Link |
|---|---|
| RO (1) | RO130480B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2600795C1 (en) * | 2015-11-19 | 2016-10-27 | Федеральное государственное бюджетное научное учреждение Всероссийский научно-исследовательский институт лекарственных и ароматических растений (ФГБНУ ВИЛАР) | Vegetable composition in the form of a micellar solution |
| RU2608126C1 (en) * | 2015-11-19 | 2017-01-13 | Федеральное государственное бюджетное научное учреждение Всероссийский научно-исследовательский институт лекарственных и ароматических растений (ФГБНУ ВИЛАР) | Anti-inflammatory composition with prolonged action for treating airway |
-
2013
- 2013-11-28 RO ROA201300916A patent/RO130480B1/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2600795C1 (en) * | 2015-11-19 | 2016-10-27 | Федеральное государственное бюджетное научное учреждение Всероссийский научно-исследовательский институт лекарственных и ароматических растений (ФГБНУ ВИЛАР) | Vegetable composition in the form of a micellar solution |
| RU2608126C1 (en) * | 2015-11-19 | 2017-01-13 | Федеральное государственное бюджетное научное учреждение Всероссийский научно-исследовательский институт лекарственных и ароматических растений (ФГБНУ ВИЛАР) | Anti-inflammatory composition with prolonged action for treating airway |
Also Published As
| Publication number | Publication date |
|---|---|
| RO130480B1 (en) | 2019-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Emran et al. | Phytochemical, antimicrobial, cytotoxic, analgesic and anti-inflammatory properties of Azadirachta indica: A therapeutic study | |
| RO130480A2 (en) | Chewable tablets with anti-inflammatory and antialgic effects, to be used in pharyngitis | |
| Munir et al. | Evaluation of antifungal and antioxidant potential of two medicinal plants: Aconitum heterophyllum and Polygonum bistorta | |
| Park et al. | Comparison of anti-inflammatory, antioxidant and anti-allergic effects of Ganoderma species mycelial extracts | |
| Sireeratawong et al. | Anti-inflammatory activity and toxicity of the water extract of Terminalia chebula rezt in rats | |
| Silva et al. | Anti-inflammatory, antinociceptive and antioxidant activities of the hydromethanolic fraction from Annona nutans leaves | |
| RU2013131625A (en) | METHOD FOR PRODUCING PARTICLES OF AN ENAPSULATED FAT-SOLUBLE POLYMERIC UNABY ENVELOPE Possessing SUPRAMOLECULAR PROPERTIES | |
| Mohammed et al. | Detarium microcarpum Stem Bark Extracts Induce Apoptosis in Human Breast Adenocarcinoma MDA MB 231 Cells via cJNK Activation and Mitochondrial Cytochrome C Release | |
| Shahriari et al. | P 19: The Effects of Aloe Vera Extract on Brain Edema and Blood-Brain Barrier Permeability after Traumatic Brain Injury | |
| Nickavar | Free radical scavenging activities of four Salvia species | |
| AbouZid | Chemical and biological studies on Tamarix nilotica growing in Egypt | |
| Zheng et al. | Terpenes and phenolic compounds from Agastache rugosa and their inhibitory effect on the release of β-hexosaminidase in RBL-2H3 cells | |
| Costa-Machado et al. | Spray freeze dried lipid nanostructures containing Copaifera langsdorfii Desf. extracts | |
| Khayyal et al. | Comparative effects of STW 5 and STW 5-II in dextran sodium sulfate-induced colitis | |
| Pereira et al. | Evaluation of the antibacterial activity of some African medicinal plants | |
| Lee et al. | Antineutrophilic inflammatory secondary metabolites from Solanum macaonense | |
| Sakpakdeejaroen et al. | Tablet formulation and stability test of thai traditional remedy for muscle pain treatment called sahasthara | |
| Zhang et al. | Evaluation of antioxidant activity of flavonoids and phloroglucinols from Guanzhong | |
| Piazzini et al. | Innovative formulations to enhance oral bioavailability of Agnus castus extract | |
| Chen et al. | The protective effect of luteolin on amyloid β protein (25–35)-induced neurotoxicity in primary rat cortical neuron cells and possible mechanisms | |
| Massaro et al. | In vitro antibacterial phenolic extracts from “sugarbag” pot-honeys of Australian stingless bees (Tetragonula carbonaria) | |
| Si et al. | Antibacterial capacity of Juglans sigillata green husks | |
| Vongsak et al. | Comparison of the free radical-scavenging activity of Thai stingless bee propolis | |
| Ahmed et al. | Evaluation of Some Medicinal Plant Extracts against Neuroinflammation Characterizing Alzheimer's Disease in Experimental Rat Model | |
| Jaijoy et al. | Anti-inflammatory activity and toxicity of the standardised water extract of Phyllanthus emblica L. |